# A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

> **NCT05121376** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BioMarin Pharmaceutical** · enrollment: 44 (estimated)

## Conditions studied

- Hereditary Angioedema
- HAE

## Interventions

- **GENETIC:** Dose 1 of BMN 331
- **GENETIC:** Dose 2 of BMN 331
- **GENETIC:** Dose 3 of BMN 331
- **GENETIC:** Dose 4 of BMN 331
- **GENETIC:** Dose 5 of BMN 331
- **GENETIC:** Dose 6 of BMN 331
- **GENETIC:** Dose 7 of BMN 331

## Key facts

- **NCT ID:** NCT05121376
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-15
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05121376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05121376, "A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05121376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*